Two 52-week trials found orforglipron reduced apnea events versus placebo in adults with sleep apnea and excess weight; FDA approval for OSA is not established.
Could A Daily Supplement Keep Blood Vessels Healthier As We Age?
A small randomized trial found improved vessel-function measures and lower systolic blood pressure after six months, but did not test cardiovascular events.